Top
This page is only for information of and use by registered medical practitioners. Other persons are advised not to act on the basis of information contained in this page. They are requested to consult registered medical practitioner.

CILACAR (Cilnidipine) is a 4th generation DHP calcium channel blocker. It is used for the treatment of hypertension.

Cilacar is marketed by JB Chemical and Pharmaceuticals limited and comes in three doses namely CILACAR 5 mg, CILACAR 10 mg and CILACAR 20 mg.

Cilnidipine is a 4th generation dihydropyridine calcium antagonist with a slow onset and long duration of action. Calcium antagonists inhibit influx of extracellular calcium ions into the cells, resulting in decreased vascular smooth muscle tone and vasodilation, leading to a reduction in blood pressure

In human studies, cilnidipine had weak inotropic effects and suppressed cardiac sympathetic overactivity. Therefore it may decrease the risk and mortality from long term cardiovascular complications. Once-daily cilnidipine was associated with less reflex tachycardia and had fewer effect on the autonomic nervous system in hypertensive patients. (see Product Leaflet,)

Overview
Name of Product : Cilacar 5mg/10mg/20mg
Manufacturer : J B Chemicals & Pharmaceuticals LTD
Medicine composition: Cilnidipine
Prescription vs.OTC: Prescription by Doctor required
Dosage Form: Tablets
  • Cilnidipine is used for treatment of hypertension.

The recommended adult oral dosage of Cilnidipine is 5-10 mg once daily. The dosage can be increased up to 20 mg, if needed. Starting dose 5 to 10 mg per day depending on individual case. Maintaining dose- physician will titrate the dose as per patient’s symptoms

Advanced aortic stenosis, Hypersensitivity to Cilnidipine or other calcium channel antagonists.

Cilnidipine should be used carefully in patients with Angina, Chronic renal insufficiency, Congestive heart failure, Hypotension, Liver dysfunction, or elevated liver enzymes and Peripheral edema (confounding physical findings in congestive failure)

Cilnidipine can interact with aldesleukin, quinidine, phenytoin, rifampicin, erythromycin, other anti-hypertensive drugs and anti-psychotic drug.

Download the Product Leaflet, to see the detailed drug interactions

Dizziness, headache, peripheral edema, flushing, rash and gingival hyperplasia are the most common adverse events seen with the dihydropyridine derivative calcium channel antagonists. Headache, Flushing was reported in 3.7 & 4.5% of 764 subjects receiving cilnidipine respectively

Also for use in specific population, Download the Product Leaflet

Download the Product Leaflet, Undesirable Side effects/ Overdose

Download the Product Leaflet, to see the details on Pharmacodynamic and Pharmacokinetic Properties of Cilacar

Contact us for further information

CILACAR (Cilnidipine) is a 4th generation DHP calcium channel blocker. It is used for the treatment of hypertension.

Cilacar is marketed by JB Chemical and Pharmaceuticals limited and comes in three doses namely CILACAR 5 mg, CILACAR 10 mg and CILACAR 20 mg.


Cilnidipine is a 4th generation dihydropyridine calcium antagonist with a slow onset and long duration of action. Calcium antagonists inhibit influx of extracellular calcium ions into the cells, resulting in decreased vascular smooth muscle tone and vasodilation, leading to a reduction in blood pressure


In human studies, cilnidipine had weak inotropic effects and suppressed cardiac sympathetic overactivity. Therefore it may decrease the risk and mortality from long term cardiovascular complications. Once-daily cilnidipine was associated with less reflex tachycardia and had fewer effect on the autonomic nervous system in hypertensive patients. (see Product Leaflet,)

Video Section